Do you work in extreme conditions? This enzyme could change your results

In the world of biotechnology, every detail matters. When it comes to enzymatic reactions at high temperatures, precision and stability are key. That’s why Cocoon Bioscience’s new thermostable pyrophosphatase is generating so much interest: an enzyme capable of maintaining its activity at 75 °C without compromising purity or process efficiency.

This recombinant enzyme, produced using Crisbio® technology, catalyzes the hydrolysis of inorganic pyrophosphate (PPi), a byproduct that can interfere with processes such as DNA or RNA synthesis. Controlled removal of PPi is essential to avoid inhibition in critical reactions, and this pyrophosphatase achieves it with over 95% purity and no detectable DNase activity.

Beyond its technical performance, it stands out for its stability of up to two years at –20 °C and its validation via spectrophotometry. This makes it an ideal tool for laboratories operating under GMP standards, where every component must meet the highest levels of traceability and control.

Are you working in enzymatic synthesis, metabolic studies, or demanding bioprocesses? This enzyme might be exactly what you need to optimize your protocols. Its excellent cost-effectiveness, combined with its robustness under high thermal conditions, positions it as a sustainable and reproducible solution in biotechnology.

Discover all the technical details and key applications of this thermostable pyrophosphatase.

https://www.abyntek.com/pirofosfatasa-termoestable-precision-enzimatica-para-condiciones-extremas/?lang=en

Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Ona Therapeutics Raises $86.6 Million Se...

by Ysios Capital

Proceeds to support clinical development of lead first-in-class progra...

Photos Stream